Navigation Links
Transplant drug 2-year study outcomes show superior kidney function
Date:5/2/2010

SAN DIEGOTwo-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

The two-year results from the three-year BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) and BENEFIT-EXT ("extended criteria") studies were presented Sunday at the American Transplant Congress in San Diego. A safety study that pooled long- term data also was presented.

In the BENEFIT trial, 666 patients were randomized to three groups and transplanted at 100 sites around the world, with 493 completing two years on treatment. In the BENEFIT-EXT study, 543 patients were randomized and transplanted, with 347 completing two years on treatment. The three treatment groups were less intensive (LI) and more intensive (MI) belatacept and a standard regimen of cyclosporine (CsA). All patients also received standard transplant regimens of the anti-T cell antibody basiliximab and drugs mycophenolate mofetil and corticosteroids.

Patient and graft survival after two years was similar among the belatacept and cyclosporine groups (94 percent MI; 95 percent LI; 91 percent CsA). The superior renal benefit of belatacept found after the first year of treatment was sustained in the second year, as measured by glomerular filtration rate. The improvement in cardiovascular/metabolic risk profile with belatacept remained in year two, with an additional beneficial effect noted in LDL cholesterol. Eight additional patients experienced an episode of acute rejection in year two (four with belatacept, four with cyclosporine), but in most cases this was successfully treated with drugs and did not lead to graft failure.

The overall incidence rate of malignancies and serious infections remained comparable across the groups. Although in the second year there remained a higher incidence of post-transplant lymphoproliferative disorder (PTLD)five belatacept patients vs. one cyclosporine patientthe overall safety profile remained similar across the groups. No additional benefits were seen in the MI vs. the LI belatacept group.

"Our goal in transplantation is to achieve a normal life span for our patients, and to have them survive dialysis-free with a functioning transplanted organ for that life span," says Christian P. Larsen, MD, DPhil, director of the Emory Transplant Center and chair of the Department of Surgery in Emory University School of Medicine.

"Today, the median survival of a transplant remains about 8-10 years, far short of what we'd like," Larsen adds. "While the calcineurin inhibitors, cyclosporine and tacrolimus, are potent immunosuppressant drugs, they are associated with multiple toxicities that limit transplant success. We have been working for years to develop new therapies that avoid the main complications and causes of death, including cardiovascular events, infections and malignancies. Our data with belatacept indicate it can better preserve kidney function while improving the risk for these complications."

Larsen, along with fellow Emory University transplant surgeon and researcher Thomas C. Pearson, MD, DPhil, Emory professor of surgery and co-director of the kidney/pancreas transplant program at the Emory Transplant Center, made significant research contributions to the development of belatacept, in collaboration with other investigators at Emory, the Yerkes National Primate Research Center, and Bristol Myers Squibb.

A third study, which pooled safety data from phase II and phase III studies over 2.4 to 7 years, found that longer-term treatment with belatacept-based regimens was generally safe. The incidence of deaths and serious adverse events were lowest in the belatacept LI group. The overall incidence of malignancies remained low, but was slightly higher in the MI group. The incidence of herpes infections and tuberculosis (mostly in endemic areas) was low overall, but higher in the belatacept groups. Fifteen cases of PTLD occurred (13 with belatacept, 2 with cyclosporine), mainly in patients not previously exposed to Epstein-Barr virus, which many humans have as a low-level chronic infection. The researchers say PTLD might be reduced by avoiding use of belatacept in Epstein-Barr-nave patients.

Belatacept is a "costimulation blocker" that inhibits one of two signals T cells require to trigger an immune response. It is a modified version of a fusion protein known as CTLA4-Ig, which mimics a regulatory molecule found on T cells and acts as a decoy. CTLA4-Ig (commercial name: abatecept/Orencis) is FDA approved to treat rheumatoid arthritis.


'/>"/>

Contact: Kathi Baker
kobaker@emory.edu
404-727-9371
Emory University
Source:Eurekalert

Related medicine news :

1. Study shows liver transplant center impacts patient outcomes
2. Extended hepatitis C treatment after liver transplant may benefit patients
3. Cancer risk for kidney transplant
4. Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment
5. Study examines global availability of treatment involving transplantation of blood stem cells
6. Cedars-Sinai heart transplantation tip sheet
7. Cell Transplantation Eyed as Treatment for Cerebral Palsy
8. Wounded Soldier Spared Diabetes With Emergency Transplant
9. Human development index linked to stem cell transplant rates and success in leukemia patients
10. Corneal Transplant Not Hurt by Long Preservation Time
11. Nu/Hart Leads The Way With Revolutionary Hair Transplant Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... Healthcare is in flux. The GOP wants ... mass media launching of story movements to highlight what's most unfair about healthcare. ... such a movement can generate the network power to improve healthcare policies in ...
(Date:12/8/2016)... ... 08, 2016 , ... Dickinson Insurance and Financial Services, an ... Rock, has initiated a charity drive to provide support and funding to the ... Hunger, Arkansas ranks first in senior hunger statewide, third in child hunger, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and ... and around the Cape Coral area, is embarking on a charity drive with the ... Florida. , The Harry Chapin Food Bank of Southwest Florida works to provide fresh ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  EIP Pharma, LLC ( www.eippharma.com ) today ... (previously code named VX-745), with the results of ... demonstrated significant Alzheimer,s disease relevant pharmacological activity.  The ... 303 (6-week treatment) are the subject of presentations ... scientific conference in San Diego, CA ...
(Date:12/8/2016)... Dignitana, a world leader in medical scalp-cooling ... creator of the award-winning, patented Boa® system, to produce ... DigniCap® scalp cooling system. DigniCap® was cleared by the ... is the first medical scalp cooling device to receive ... features a patented tight-fitting silicone cooling cap that is ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... dedicated to improving cancer patient care from diagnosis ... the company,s recently completed Phase 1b study in ... at the San Antonio Breast Cancer Symposium. ... Cancer Center at UC San Diego Health, delivered ...
Breaking Medicine Technology: